India introduces CRISPR therapy BIRSA 101 for sickle cell disease

India has made a significant advancement in medical technology with the launch of BIRSA 101, its first homegrown CRISPR-based gene therapy designed to treat sickle cell disease. This hereditary blood disorder leads to painful crises, anemia, and potential organ damage. Developed at the CSIR–Institute of Genomics & Integrative Biology (IGIB), BIRSA 101 aims to alleviate the disease burden particularly among tribal populations in central and eastern India. The therapy employs CRISPR technology to edit patients’ stem cells, effectively addressing the root cause of the disease by modifying the stem cells and reinfusing them to produce healthy red blood cells.

The introduction of BIRSA 101 follows successful Phase 1 clinical trials involving three patients. This research was funded by the Department of Science & Technology (DST) and facilitated by the Ministry of Tribal Affairs. Souvik Maiti, Director of CSIR-IGIB, emphasized that traditional global therapies are often prohibitively expensive, highlighting the need for an indigenous solution that is both effective and affordable. The collaboration with the Serum Institute of India Pvt. Ltd. aims to enable large-scale production of the therapy, making it accessible to those who need it.

This gene therapy is named in honor of Birsa Munda, a tribal freedom fighter, coinciding with the celebration of his 150th birth anniversary. Union Minister of State for Science & Technology, Dr. Jitendra Singh, noted that the launch signifies a critical step toward achieving a sickle cell disease-free nation. He described BIRSA 101 as a form of “precise genetic surgery” that has the potential not only to cure sickle cell disease but also to transform treatment approaches for various hereditary disorders, marking a milestone in India’s medical advancements.

Beyond its immediate medical implications, the introduction of BIRSA 101 carries broader social benefits, especially for tribal communities where the prevalence of sickle cell disease is notably high. The development of affordable therapies will help reduce health disparities and improve the quality of life for affected populations. Additionally, this initiative showcases India’s capability to develop advanced medical therapies at a fraction of the cost compared to international markets, potentially replacing treatments that can cost between Rs 20–25 crore abroad.

Looking ahead, the successful implementation of BIRSA 101 could pave the way for further innovations in gene therapy and other advanced medical treatments within India. The ongoing collaboration between research institutions and production facilities will be crucial for scaling up the therapy and ensuring its widespread availability. As India continues to progress in the field of genetic medicine, the significance of BIRSA 101 lies not only in its potential to treat sickle cell disease but also in its role as a catalyst for future advancements in public health.